semaglutide nausea class action in louisiana glp-1 gi obstruction lawsuit gastrointestinal gastric intestinal obstruction attorney louisiana Ozempic GLP-1 & Gastroparesis-mvanhaasteren.nl glp-1 class action in – Peptide boom has states scrambling

Our intervention used existing clinical reports and a limited amount of nurse and clinical pharmacy practitioner (CPP) time (in addition to regular scheduled patient care)

It cannot be prescribed by physicians through normal channels

Until tirzepatide's SURPASS-CVOT data is published, semaglutide has the stronger evidence for heart health

Semgalutide's efficacy in restoring glucose homeostasis to treat T2D has been demonstrated in rigorous trials on type 2 diabetic patients.Phase 3 studies of semaglutide in T2D patients revealed substantial decreases in blood HbA1c as well as fasting plasma glucose (FPG) levels after just 12 weeks of once-weekly subcutaneous treatment [4]

This head-to-head comparison examines both peptide injections through the lens of clinical evidence, mechanism of action, safety data, and real-world availability in 2026